USE OF ALKALINE PHOSPHATASE FOR PRESERVING RENAL FUNCTION
The invention relates to the field of medicine and in particular to means and methods for preserving renal function after a treatment with a risk of reducing renal function. The present invention also relates to means and methods for shortening the duration of renal replacement therapy, increasing the creatinine clearance and decreasing the adverse effects of medicaments.
1 - 29 . (canceled)
30 . A method for at least in part preserving and/or increasing renal function after a treatment with a risk of reducing renal function in a subject, comprising administering alkaline phosphatase to the subject.
31 . A method for at least in part preserving and/or increasing glomerular filtration rate (GFR) in a subject undergoing a treatment with a risk of decreasing GFR and/or renal creatinine clearance, the method comprising: administering alkaline phosphatase before said treatment, thereby at least in part preserving and/or increasing said GFR, and determining said preserved and/or increased GFR at least 7 days after said treatment.
32 . A method for determining whether a subject undergoing a treatment with a risk of decreasing GFR and/or renal creatinine clearance responds well to an alkaline phosphatase treatment for at least in part preserving and/or increasing GFR, the method comprising administering alkaline phosphatase before said treatment; determining GFR at baseline and/or on the first day after the start of alkaline phosphatase administration; determining GFR on the second and/or third day after the start of alkaline phosphatase administration, wherein an increase of said GFR and/or said renal creatinine clearance on the second and/or third day, relative to said GFR and/or said renal creatinine clearance at baseline and/or on the first day is indicative for said subject responding well to said alkaline phosphatase treatment; and determining whether said individual responds well to said alkaline phosphatase treatment.
33 . A method for shortening duration of renal replacement therapy (RRT) in a subject undergoing RRT, the method comprising:
administering alkaline phosphatase before, during and/or after said subject undergoes RRT; and
determining renal function before, during and/or after said subject undergoes RRT; and
discontinuing RRT in said subject when said renal function has been increased to and/or preserved at a threshold value, thereby shortening duration of RRT in said subject.
34 . A method for decreasing the amount of (co)medication, the method comprising administering alkaline phosphatase to a subject receiving said (co)medication or being at risk of receiving said (co)medication.
35 . A method for decreasing adverse effects of (co)medication in a subject receiving said (co)medication or being at risk of receiving said (co)medication, the method comprising administering alkaline phosphatase before, during and/or after said subject receives said medication, thereby decreasing adverse effects of said (co)medication in said subject.
36 . A method according to claim 34 , wherein said (co)medication is for the treatment of a heart condition.
37 . A method according to claim 36 , wherein the (co)medication is a class III anti-arrhythmic, a selective β-blocker, a digitalis glycoside, a vitamin K antagonist, or a selective β-2-adrenoceptor agonist.
38 . A method for preventing and/or treating atrial fibrillation, the method comprising administering alkaline phosphatase to a subject suffering or at risk of suffering from atrial fibrillation, thereby preventing or treating said atrial fibrillation.
39 . A method according to claim 38 , wherein said atrial fibrillation is due to decreased renal creatinine clearance.
40 . The method according to claim 38 , wherein (co)medication for the treatment of atrial fibrillation is decreased.
41 . The method according to claim 38 , wherein said atrial fibrillation is due to (co)medication.
42 . The method of claim 41 , wherein the (co)medication is a class III anti-arrhythmic, a selective β-blocker, a digitalis glycoside, a vitamin K antagonist, or a selective β-2-adrenoceptor agonist.
43 . The method according to claim 41 , wherein (co)medication for the treatment of atrial fibrillation is decreased.
44 . The method according to claim 38 , wherein said subject is an intensive care unit patient.
45 . The method of claim 30 , wherein said treatment with a risk of reducing renal function is selected from the group consisting of renal replacement therapy, exposure to intravascular contrast media, kidney and/or heart surgery, kidney and/or heart transplantation, blood transfusion, red blood cell transfusion, drug treatment and/or surgical re-exploration, and combinations thereof, and
wherein said preserving and/or increasing renal function is at least in part due to a reduction in the amount of (co)medication for the treatment of a heart condition.
46 . The method according to claim 45 , wherein said heart condition, resulted from myocardial infarction or heart failure.
47 . The method according to claim 35 , wherein said (co)medication is for the treatment of a heart condition.
48 . The method according to claim 36 , wherein said heart condition, resulted from myocardial infarction or heart failure.
49 . The method according to claim 47 , wherein said heart condition, resulted from myocardial infarction or heart failure.